What is AusperBio?
AusperBio operates at the intersection of biotechnology and precision medicine, with a dual-presence in the USA and China. The company is primarily focused on the development of its proprietary Med-Oligo ASO platform, which is engineered to enhance the efficacy of antisense oligonucleotide therapeutics. By integrating novel ASO design insights with advanced targeted delivery conjugation technologies, AusperBio is addressing a diverse spectrum of medical needs, including viral infections, metabolic conditions, and immune-mediated diseases. Its lead program targets a functional cure for chronic hepatitis B, positioning the firm as a high-impact entity within the global biopharmaceutical sector.
How much funding has AusperBio raised?
AusperBio has raised a total of $330M across 4 funding rounds:
Series A
$37M
Other Financing Round
$50M
Series B
$123M
Series C
$120M
Series A (2024): $37M with participation from Genesis Capital, YuanBio Venture Capital, and Qiming Venture Partners
Other Financing Round (2025): $50M led by Qiming Venture Partners, Sherpa Capital, Genesis Capital, YuanBio Venture Capital, CDH Investments, and HanKing Mould
Series B (2025): $123M supported by Qiming Venture Partners, CDH Investments, Sherpa Capital, and YuanBio Venture Capital
Series C (2026): $120M featuring CDH Investments, YuanBio Venture Capital, Qiming Venture Partners, RA Capital Management, and Sherpa Capital
Key Investors in AusperBio
Qiming Venture Partners
A prominent venture capital firm focusing on innovative healthcare and technology companies, providing strategic guidance and industry resources to foster long-term growth.
CDH Investments
A diversified investment firm with extensive experience in private equity and public markets, supporting high-potential enterprises across various sectors.
YuanBio Venture Capital
A specialized healthcare venture capital firm based in Suzhou, dedicated to early and growth-stage investments in life sciences and precision medicine.
What's next for AusperBio?
With the successful closure of its latest financing, AusperBio is well-positioned to accelerate its clinical development pipeline and expand the modular capabilities of its Med-Oligo platform. The strategic focus will likely shift toward advancing lead candidates through late-stage clinical trials while simultaneously exploring new therapeutic applications for its delivery technology. As the company transitions from a development-focused entity to a more mature clinical-stage organization, the emphasis will remain on achieving regulatory milestones and establishing long-term value through scientific innovation and strategic partnerships in the global healthcare market.
See full AusperBio company page
